FI934849A0 - Sammansaettningar foer foerhindrande och/eller behandlande av patologiskaprocesser - Google Patents

Sammansaettningar foer foerhindrande och/eller behandlande av patologiskaprocesser

Info

Publication number
FI934849A0
FI934849A0 FI934849A FI934849A FI934849A0 FI 934849 A0 FI934849 A0 FI 934849A0 FI 934849 A FI934849 A FI 934849A FI 934849 A FI934849 A FI 934849A FI 934849 A0 FI934849 A0 FI 934849A0
Authority
FI
Finland
Prior art keywords
lmwh
present
pathological processes
sale
production
Prior art date
Application number
FI934849A
Other languages
English (en)
Other versions
FI934849A (fi
Inventor
Irun R Cohen
Ofer Lider
Rami Hershkoviz
Original Assignee
Yeda Res & Dev
Irun R Cohen
Ofer Lider
Rami Hershkoviz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL9802891A external-priority patent/IL98028A/en
Priority claimed from IL98298A external-priority patent/IL98298A0/xx
Application filed by Yeda Res & Dev, Irun R Cohen, Ofer Lider, Rami Hershkoviz filed Critical Yeda Res & Dev
Publication of FI934849A0 publication Critical patent/FI934849A0/fi
Publication of FI934849A publication Critical patent/FI934849A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
FI934849A 1991-05-02 1993-11-02 Sammansaettningar foer foerhindrande och/eller behandlande av patologiskaprocesser FI934849A (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL9802891A IL98028A (en) 1991-05-02 1991-05-02 Pharmaceuticals containing low molecular weight heparin (HWML)
IL98298A IL98298A0 (en) 1991-05-28 1991-05-28 Pharmaceutical compositions comprising a heparin derivative
PCT/US1992/003626 WO1992019249A1 (en) 1991-05-02 1992-05-01 Compositions for the prevention and/or treatment of pathological processes

Publications (2)

Publication Number Publication Date
FI934849A0 true FI934849A0 (fi) 1993-11-02
FI934849A FI934849A (fi) 1993-12-31

Family

ID=26322260

Family Applications (1)

Application Number Title Priority Date Filing Date
FI934849A FI934849A (fi) 1991-05-02 1993-11-02 Sammansaettningar foer foerhindrande och/eller behandlande av patologiskaprocesser

Country Status (15)

Country Link
US (3) US5474987A (fi)
EP (1) EP0583360B1 (fi)
JP (1) JPH06507635A (fi)
KR (1) KR100235782B1 (fi)
AT (1) ATE217796T1 (fi)
AU (1) AU668865B2 (fi)
BR (1) BR9205961A (fi)
CA (1) CA2102207A1 (fi)
CZ (1) CZ232593A3 (fi)
DE (1) DE69232615T2 (fi)
FI (1) FI934849A (fi)
HU (1) HUT67136A (fi)
NO (1) NO933942L (fi)
SK (1) SK120193A3 (fi)
WO (1) WO1992019249A1 (fi)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605938A (en) 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
US6750207B1 (en) * 1992-05-01 2004-06-15 Yeda Research And Development Co. Ltd. Compositions for the regulation of cytokine activity
WO1994011006A1 (en) * 1992-11-10 1994-05-26 Yeda Research And Development Co. Ltd. Compositions for the regulation of cytokine activity
AU6204594A (en) * 1993-02-22 1994-09-14 Ulrich-Christoph Von Arnim Use of heparins for the treatment of inflammatory or immunological diseases
US5980865A (en) * 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
US6217863B1 (en) 1995-10-30 2001-04-17 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from heparinase I
WO1998023279A1 (en) * 1996-11-27 1998-06-04 Rhone-Poulenc Rorer Pharmaceuticals Inc. PHARMACEUTICAL COMPOSITION COMPRISING A COMPOUND HAVING ANTI-Xa ACTIVITY AND A PLATELET AGGREGATION ANTAGONIST COMPOUND
DE69835016T2 (de) * 1997-07-14 2007-06-28 Muramatsu, Takashi, Nagoya Verwendung von midkin oder von anti-midkin antikörper
WO2000012726A2 (en) 1998-08-27 2000-03-09 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase i and ii
US7056504B1 (en) 1998-08-27 2006-06-06 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase I and II
IL127851A0 (en) * 1998-12-30 1999-10-28 Applied Research Systems Inhibition of TNF activity
EP1190364A2 (en) * 1999-04-23 2002-03-27 Massachusetts Institute Of Technology System and method for polymer notation
CA2377734A1 (en) * 1999-06-30 2001-01-11 Hamilton Civic Hospitals Research Development, Inc. Heparin compositions that inhibit clot associated coagulation factors
EP1266013B1 (en) 2000-03-08 2014-10-15 Massachusetts Institute Of Technology Heparinase iii and uses thereof
HUP0300939A2 (hu) * 2000-09-08 2003-09-29 Hamilton Civic Hospitals Research Development, Inc. Antitrombotikus készítmények
WO2002023190A2 (en) 2000-09-12 2002-03-21 Massachusetts Institute Of Technology Methods and products related to low molecular weight heparin
CA2423469A1 (en) 2000-10-18 2002-04-25 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
WO2002047696A1 (de) * 2000-12-16 2002-06-20 Aventis Pharma Deutschland Gmbh Verwendung von niedermolekularen heparin zur behandlung von osteoarthrose
WO2003000190A2 (en) * 2001-06-25 2003-01-03 Depuy Liposomal encapsulation of glycosaminoglycans for the treatment of arthritic joints
US20030036103A1 (en) * 2001-07-31 2003-02-20 Sivaram Pillarisetti Methods and compositions for diagnosis and treatment of vascular conditions
CA2455038A1 (en) * 2001-07-31 2003-02-13 Board Of Regents, University Of Texas System Antigens of and antibodies to translocated molecules of microorganisms and uses thereof
US7285536B2 (en) * 2001-12-05 2007-10-23 Yeda Research And Development Co., Ltd. Anti-cancer therapeutic compounds
AU2003230985A1 (en) * 2002-04-18 2003-11-03 Stephen H. Embury Method and composition for preventing pain in sickle cell patients
US8071569B2 (en) * 2002-09-20 2011-12-06 Mousa Shaker A Oxidized heparin fractions and their use in inhibiting angiogenesis
CA2514474C (en) * 2003-01-30 2014-05-06 Avner Yayon Freeze-dried fibrin matrices and methods for preparation thereof
WO2005054493A2 (en) * 2003-06-12 2005-06-16 Mayo Foundation For Medical Education And Research Altered activity of toll-like receptors
CA2530533C (en) 2003-06-27 2015-02-10 Ethicon, Incorporated Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
US20060223177A1 (en) 2003-06-27 2006-10-05 Ethicon Inc. Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
AU2004278013B2 (en) * 2003-10-01 2009-01-15 Momenta Pharmaceuticals, Inc. Polysaccharides for pulmonary delivery of active agents
CN1819833A (zh) * 2004-03-29 2006-08-16 克霖固鲁制药股份有限公司 促进hgf产生的含肝素类寡糖的药剂
US8450297B2 (en) * 2004-08-16 2013-05-28 Massachusetts Institute Of Technology Rapid two-step synthesis of anti-coagulants
CA2616166A1 (en) * 2005-07-22 2007-02-01 The Regents Of The University Of California Heparin compositions and selectin inhibition
US8921109B2 (en) 2005-09-19 2014-12-30 Histogenics Corporation Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof
AU2009250803A1 (en) * 2008-05-20 2009-11-26 Crystal Clear Partnership Separation of polysaccharides by charge density gradient
US10077420B2 (en) 2014-12-02 2018-09-18 Histogenics Corporation Cell and tissue culture container

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL61201A (en) * 1979-10-05 1984-09-30 Choay Sa Oligosaccharides having no more than 8 saccharide moieties,their obtention from heparin and pharmaceutical compositions containing them
US4281108A (en) * 1980-01-28 1981-07-28 Hepar Industries, Inc. Process for obtaining low molecular weight heparins endowed with elevated pharmacological properties, and product so obtained
DK168876B1 (da) * 1982-12-20 1994-07-04 Harvard College Middel, der kan administreres oralt eller subcutant, til inhibering af angiogenese hos pattedyr samt fremgangsmåde til fremstilling af et sådant middel
US4916219A (en) * 1985-03-28 1990-04-10 University Of Iowa Research Foundation Oligosaccharide heparin fragments as inhibitors of complement cascade
IT1214609B (it) * 1985-05-17 1990-01-18 Opocrin Spa Esosaminoglicani solfati depolimerizzati ad attivita'antitrombotica, fibrinolitica, antinfiammatoria, loro procedimento di preparazione e composizioni farmaceutiche che li contengono.
US4889808A (en) * 1985-10-01 1989-12-26 American Home Products Method of enchancing t-PA and SCU-PA production
EP0240098A3 (en) * 1986-04-04 1989-05-10 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Oligo and polysaccharides for the treatment of diseases caused by retroviruses
US4788307A (en) * 1986-04-30 1988-11-29 Choay S.A. Oligosaccharidic fractions devoid or practically devoid of antithrombotic activity
DE3787996T2 (de) * 1986-05-16 1994-03-03 Italfarmaco Spa Heparine, frei von E.D.T.A., Fraktionen und Fragmente von Heparin, Verfahren zu deren Herstellung und pharmazeutische Zusammensetzungen, welche diese enthalten.
WO1988000017A1 (en) * 1986-06-27 1988-01-14 Boon Corporation Pty. Ltd. Mat
IL85145A (en) * 1987-01-23 1994-08-26 Univ Australian Anti-metastatic pharmacological or veterinary preparations containing modified herpin with reduced anticoagulant activity
FR2614026B1 (fr) * 1987-04-16 1992-04-17 Sanofi Sa Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
SE8702254D0 (sv) * 1987-05-29 1987-05-29 Kabivitrum Ab Novel heparin derivatives
WO1990003791A1 (en) * 1988-10-05 1990-04-19 Nicola Diferrante Methods for interfering with hiv multiplication and composition for the treatment of aids
IL88554A0 (en) * 1988-12-01 1989-07-31 Hadassah Med Org Compositions containing a compound binding to a heparin receptor
PT93847A (pt) * 1989-04-24 1990-11-20 Harvard College Processo para a preparacao de oligossacaridos de baixo peso molecular derivados de heparina ou de sulfato de heparano despolimerizados e de composicoes farmaceuticas que os contem
AT500533B8 (de) * 2000-04-13 2007-02-15 Man Nutzfahrzeuge Ag Gas- oder trolleybus

Also Published As

Publication number Publication date
ATE217796T1 (de) 2002-06-15
JPH06507635A (ja) 1994-09-01
BR9205961A (pt) 1994-07-26
WO1992019249A1 (en) 1992-11-12
DE69232615D1 (de) 2002-06-27
US5474987A (en) 1995-12-12
EP0583360A1 (en) 1994-02-23
AU1913192A (en) 1992-12-21
CZ232593A3 (en) 1994-07-13
HUT67136A (en) 1995-02-28
SK120193A3 (en) 1994-07-06
DE69232615T2 (de) 2003-01-30
EP0583360B1 (en) 2002-05-22
CA2102207A1 (en) 1992-11-03
NO933942L (no) 1993-12-14
US5908837A (en) 1999-06-01
FI934849A (fi) 1993-12-31
KR100235782B1 (ko) 1999-12-15
NO933942D0 (no) 1993-11-01
HU9303110D0 (en) 1994-01-28
AU668865B2 (en) 1996-05-23
US5686431A (en) 1997-11-11
EP0583360A4 (fi) 1994-04-06

Similar Documents

Publication Publication Date Title
FI934849A0 (fi) Sammansaettningar foer foerhindrande och/eller behandlande av patologiskaprocesser
DK0756461T3 (da) Tobaksprodukter eller tobaksproduktlignende varer med antioxidativt virkende naturstoffer og fremgangsmåde til fremstilling
ES500122A0 (es) Procedimiento para preparar un producto con actividad de ti-po fibronectina
IT8349510A0 (it) Procedimento per la produzione di acido ialuronico da colture batteriche
NO177785C (no) Analogifremgangsmåter for fremstilling av terapeutisk aktive alkoksy-4(1H)-pyridonderivater
Wilson et al. Modulation of plasminogen activator synthesis in chick embryo fibroblasts by cyclic nucleotides and phorobol myristate acetate
DE69533941D1 (de) Verfahren zur herstellung eines arzneimittels zur behandlung des sekundärimmunmangels
SE9600716L (sv) Adhesionsinhibitorer, preparat innehållande desamma och förfarande för framställning därav
EP0460062A4 (en) Method for the synthesis of huperzine a and analogs thereof and compounds useful therein
EP0669827B1 (en) Compositions for the regulation of cytokine activity
ES551434A0 (es) Proceso para la fabricacion de compuestos de espiro-hidantoina
ES8302090A1 (es) Un procedimiento para la preparacion del nuevo antibiotico bmo162-af2, obtenido mediante el cultivo de una cepa perte- neciente al genero bacillus.
EE9900044A (et) Farmatseutilised tooted veresoonte endoteelirakkude kahjustuste tagajärjel tekkinud haiguste raviks ja vältimiseks
Sturman et al. Host dependence of GDVII virus: complete or abortive multiplication in various cell types
FR2378855A1 (fr) Nouvelles glycoproteines isolees d'hafnia, procede de preparation et application a titre de medicaments
Savion et al. Murine macrophage heparanase: inhibition and comparison with metastatic tumor cells
JPS5679622A (en) Antitumor pharmaceutical
DE69433110D1 (de) Allogenes vakzin und synthesemethode für selbiges
HUT70507A (en) Process for producing pharmaceutical compositions containing beta-naphtoquinone derivatives with epithalial proliferation fastening and no-synthetase inhibiting activity and process to prepare them
ES476703A1 (es) Procedimiento para preparar una heterovacuna para el trata -miento terapeutico del sindrome de los triconomas.
RU93058322A (ru) Композиции для предотвращения и/или лечения патологических процессов, способ применения низкомолекулярного гепарина, способ лечения
Cohen et al. Methods of using low molecular weight heparins treatment of pathological processes
AU650910B2 (en) Use of a heparinfraction
NO974651L (no) Biologisk aktive ureidoderivater som er nyttige i behandlingen av multippel sklerose
SE8306792L (sv) Nytt terapeutiskt preparat innehallande hydrerade ergotalkaloider och heparin

Legal Events

Date Code Title Description
FD Application lapsed